Trade AbCellera Biologics Inc - ABCL CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.05
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$1.11)Trade size with leverage ~ $5,000.00Money from leverage ~ $$4,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $5,000.00Money from leverage ~ $$4,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$1.11)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 12.64
• Open: 12.48
• 1-Year Change: 104.93%
• Day's Range: 11.7 - 12.48

Trade AbCellera Biologics Inc - ABCL

AbCellera Biologics Inc. (ABCL) is a Canadian biotechnology company that develops antibody discovery platforms. Its full-stack, AI-powered drug discovery platform searches and analyses the database of natural immune systems to find antibodies that can be used by its partners to develop into drugs. 

ABCL was established in 2012 as a spin-off from the University of British Columbia (UBC), where Dr Carl Hansen, the company’s founding CEO, was a faculty member from 2005 to 2019.

The Vancouver-based company has collaborations with drug developers ranging from large cap pharmaceuticals to small biotechnology firms. As of the earnings date of 31 December 2021, the company had 156 discovery programmes either completed, in progress or under contract with 36 partners.

As a recent example, AbCellera Biologics teamed with pharma giant Eli Lilly (LLY) to co-develop two antibody therapeutics to treat and prevent Covid-19 utilising ABCL’s technological stack.

Some of the pharmaceutical companies that partnered with ABCL in the past two years include Everest Medicines for oncology or cancer; Kodiak Sciences (KOD) for partnership in eye care, Novarties (NVS), and Gilead Sciences (GILD) for infectious disease. 

AbCellera Biologics was listed as a public company and began trading on the NASDAQ stock exchnage under the ticker symbol ‘ABCL’ in December 2020 through an initial public offering (IPO). ABCL’s stock price was set at $20.

You can follow the ups and downs of the ABCL’s stock price at Capital.com. Also, stay on top of the latest AbCellera Biologics’ stock price developments with our live ABCL stock chart.